FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 12, 2026
Onkure Therapeutics, Inc. (OKUR) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$51.9 million. As of Sep 30, 2026 it held $163.3 million in cash and investments and $790,000 in total debt.
Revenue
$0
Net income
$-59.52M
-13.0% vs prior year
Operating cash flow (TTM)
$-47.89M
+24.8% vs year-ago TTM
Free cash flow (TTM)
$-47.94M
+24.8% vs year-ago TTM
EPS
$-4.40
+71.2% vs prior year
Dividend per share
None
Shares outstanding
13.67M
-59.1% vs prior year
Net cash
$162.51M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OKUR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boulder, CO
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1637715
- Former names
- Reneo Pharmaceuticals, Inc. (until Oct 2, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — |
| Operating income | -$63.0M | -$54.4M | -$36.9M | -$53.8M | -$39.8M |
| Net income | -$59.5M | -$52.7M | -$35.3M | -$52.0M | -$39.8M |
| Diluted EPS | -$4.40 | -$15.28 | -$124.41 | -$2.12 | -$2.19 |
| Operating cash flow | -$51.8M | -$51.1M | -$34.5M | -$47.4M | -$38.0M |
| Free cash flow | -$51.9M | -$51.2M | -$34.8M | -$47.7M | -$38.2M |
| Total assets | $62.1M | $114.9M | $35.7M | $108.2M | $154.0M |
| Total liabilities | $5.9M | $11.1M | $7.8M | $8.2M | $6.8M |
| Stockholders' equity | $56.2M | $103.8M | -$101.8M | -$54.4M | $147.2M |
| Cash and investments | $59.0M | $110.8M | $105.2M | $101.2M | $147.7M |
| Total debt | $549,000 | $1.1M | $674,000 | $1.5M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 13, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
All 404 Onkure Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.